Trial · NCT02057575

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575, Phase 2, Completed, Aerie Pharmaceuticals; results first posted 2019-06-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure. Trials, record NCT02057575. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02057575

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
NCT number: NCT02057575
Status: Completed
Phases: Phase 2
Enrollment: 298 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
First posted: 2014-02-07
Last updated: 2019-06-04
Results first posted: 2019-06-04

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	Study treatment was administered for 28 days, and outcome measures collected on Day 29	The primary efficacy endpoint was the mean diurnal IOP across subjects within treatment group at Day 29.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	Study treatment was administered for 28 days, and outcome measures collected on Day 29	Modified intent to treat (mITT) population	mmHg	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution 0.01%	Day 1, Diurnal Mean	25.11	Standard Deviation 2.330	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution 0.02%	Day 1, Diurnal Mean	25.12	Standard Deviation 2.374	mmHg
Intraocular Pressure (IOP)	Netarsudil (AR-13324) Ophthalmic Solution	Day 1, Diurnal Mean	25.35	Standard Deviation 2.666	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution	Day 1, Diurnal Mean	25.99	Standard Deviation 2.828	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution 0.01%	Day 29, Diurnal Mean	17.33	Standard Deviation 2.770	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution 0.02%	Day 29, Diurnal Mean	16.52	Standard Deviation 2.992	mmHg
Intraocular Pressure (IOP)	Netarsudil (AR-13324) Ophthalmic Solution	Day 29, Diurnal Mean	19.13	Standard Deviation 3.219	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution	Day 29, Diurnal Mean	18.44	Standard Deviation 2.565	mmHg

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PG324 Ophthalmic Solution 0.01%	74
Overall Study	STARTED	PG324 Ophthalmic Solution 0.02%	73
Overall Study	STARTED	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	78
Overall Study	STARTED	Latanoprost Ophthalmic Solution 0.005%	73
Overall Study	COMPLETED	PG324 Ophthalmic Solution 0.01%	73
Overall Study	COMPLETED	PG324 Ophthalmic Solution 0.02%	69
Overall Study	COMPLETED	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	78
Overall Study	COMPLETED	Latanoprost Ophthalmic Solution 0.005%	72
Overall Study	NOT COMPLETED	PG324 Ophthalmic Solution 0.01%	1
Overall Study	NOT COMPLETED	PG324 Ophthalmic Solution 0.02%	4

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events32

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctival Hyperaemia	Eye disorders	PG324 Ophthalmic Solution 0.01%	29	73	29
other	Conjunctival Hyperaemia	Eye disorders	PG324 Ophthalmic Solution 0.02%	29	73	29
other	Conjunctival Hyperaemia	Eye disorders	Netarsudil (AR-13324) Ophthalmic Solution	27	78	27
other	Conjunctival Hyperaemia	Eye disorders	Latanoprost Ophthalmic Solution	9	73	9
other	Lacrimation Increased	Eye disorders	PG324 Ophthalmic Solution 0.01%	1	73	1
other	Lacrimation Increased	Eye disorders	PG324 Ophthalmic Solution 0.02%	4	73	4
other	Lacrimation Increased	Eye disorders	Netarsudil (AR-13324) Ophthalmic Solution	1	78	1
other	Lacrimation Increased	Eye disorders	Latanoprost Ophthalmic Solution	0	73	0
other	Instillation Site Erythema	General disorders	PG324 Ophthalmic Solution 0.01%	11	73	11
other	Instillation Site Erythema	General disorders	PG324 Ophthalmic Solution 0.02%	14	73	14

1 to 10 of 32Source ClinicalTrials.gov

See all 32 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PG324 Ophthalmic Solution 0.01%	0	74
Total, all-cause mortality	PG324 Ophthalmic Solution 0.02%	0	73
Total, all-cause mortality	Netarsudil (AR-13324) Ophthalmic Solution	0	78
Total, all-cause mortality	Latanoprost Ophthalmic Solution	0	73
Total, other adverse events	PG324 Ophthalmic Solution 0.01%	46	73
Total, other adverse events	PG324 Ophthalmic Solution 0.02%	55	73
Total, other adverse events	Netarsudil (AR-13324) Ophthalmic Solution	49	78
Total, other adverse events	Latanoprost Ophthalmic Solution	12	73
Total, serious adverse events	PG324 Ophthalmic Solution 0.01%	0	74
Total, serious adverse events	PG324 Ophthalmic Solution 0.02%	0	73

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
26209587	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02057575

GET https://conductscience.org/api/trials/v1/NCT02057575/events?page=2

API reference For AI assistants